ScreenerHero

PRAX Praxis Precision Medicines, Inc.

NAS · US · Healthcare · Biotechnology · praxismedicines.com
278.02USD-0.76%Mkt Cap: 7.76B $P/E: —

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.76B USD
Enterprise Value7.06B USD
Revenue (TTM)—
Gross Profit-290.71M USD
Net Income (TTM)-303.27M USD
Revenue/Share—
Last Price278.02 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees168
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-30.02
PEG—
EV/EBITDA-18.69
EV/Revenue—
P/S—
P/B5.83
EPS (TTM)-12.78
EPS (Forward)-9.33
52W Range
46.9967% of range392.70
52W High392.70 USD
52W Low46.99 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.54%
ROA-32.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-249.07M USD
CapEx (TTM)56.00K USD
FCF Margin—
FCF Yield-2.57%
Net Debt-757.46M USD
Net Debt/EBITDA2.00
Balance Sheet
Debt/Equity0.00
Current Ratio15.73
Quick Ratio15.46
Book Value/Sh48.04 USD
Cash/Share27.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateNov 29, 2023
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)644.42 USD
Upside (mean)+131.8%
Target Range188.00 USD – 1201.00 USD
188.00+131.8% to mean1201.00
# Analysts19
Ownership
Shares Out.27.92M
Float24.08M
Insiders0.28%
Institutions123.42%
Short Interest
Short Ratio11.9d
Short % Float13.63%
Short % Out.13.59%
Shares Short3.80M
Short (prev mo.)3.71M
Technical
SMA 50332.22 (-16.3%)
SMA 200316.72 (-12.2%)
Beta2.81
S&P 52W Chg16.45%
Avg Vol (30d)426.47K
Avg Vol (10d)541.88K
Technical Indicators
RSI (14)34.4
MACD-16.1293
MACD Signal-14.7520
MACD Hist.-1.3773
BB Upper358.63 USD
BB Middle304.63 USD
BB Lower250.62 USD
BB Width35.45%
ATR (14)16.21 USD
Vol Ratio (20d)1.01x